Ergosterol Synthesis Inhibitors Market Share

APAC Market Statistics

Regionally, the global ergosterol synthesis inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific is likely to dominate majority revenue share by 2036, on the back of rising prevalence of fungal infections, in tropical countries, such as, Indonesia, Thailand, and India. India witnessed 5 to 10 cases of fungal infection per 1,000 individuals, in 2019. The share in Thailand amounted 12-15 cases per 1000 individuals. Moreover, growing medical infrastructure and improving public healthcare system, backed by economic growth in the region, is estimated to boost the market growth.

Latin America Market Analysis

The ergosterol synthesis inhibitors market in the Latin America region is estimated to witness noteworthy growth over the forecast period, owing to the rising incidences of infections backed by the climatic conditions favorable for fungal infections, along with unavailability of proper sanitization and cleanliness is estimated to boost the market growth.

Frequently Asked Questions (FAQ)

Ergosterol Synthesis Inhibitors Market size is expected to expand at significant growth rate during the forecast period i.e., between 2024-2036.

Recurring seasonal prevalence of influenza, coupled with government initiatives to curb the outbreak of influenza will boost the market growth.

Asia Pacific is likely to dominate majority revenue share by 2036, on the back of rising prevalence of fungal infections, in tropical countries, such as, Indonesia, Thailand, and India.

The major players in the market are Pfizer Inc., Novartis AG, Kramer Laboratories, Inc., Abbott Laboratories, Bayer AG, GlaxoSmithKline plc, and others.

Ergosterol Synthesis Inhibitors Market Share